Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FX Other monoclonal antibodies and antibody drug conjugates
L01FX14 Polatuzumab vedotin
D10761 Polatuzumab vedotin (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Anti-CD76b Antibodies
Polatuzumab Vedotin
D10761 Polatuzumab vedotin (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10761 Polatuzumab vedotin (USAN); Polatuzumab vedotin (genetical recombination) (JAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
D10761 Polatuzumab vedotin
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD79B
D10761 Polatuzumab vedotin (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10761
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10761
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10761
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10761
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10761
